Literature DB >> 25327574

Identification of potential genomic biomarkers for Sjögren's syndrome using data pooling of gene expression microarrays.

Sadik A Khuder1, Ibtisam Al-Hashimi, Anand B Mutgi, Nezam Altorok.   

Abstract

Sjögren's syndrome (SS) is an autoimmune disease characterized by lymphocytic infiltration and destruction of salivary and lacrimal glands. The diagnosis of SS can be challenging due to lack of a specific test for the disease. The purpose of this study is to examine the accuracy of using gene expression profile for diagnosis of SS. We identified 9 publically available datasets that included gene expression data from saliva and salivary gland biopsy samples of 52 patients with SS and 51 controls. Out of these datasets, we compiled and pooled data from three datasets that included 37 and 29 samples from SS patients and healthy controls, respectively, which were designated as "training set." Then, we performed cross-listing in a group of independent gene expression datasets from patients with SS to identify consensus gene list of differentially expressed genes. We performed Linear Discriminant Analysis (LDA) to quantify the accuracy of discriminating genes to predict SS in both the "training set" and an independent group of datasets that was designated as "test set." We identified 55 genes as potential classifier genes to differentiate SS from healthy controls. An LDA by leave-one-out cross-validation method identified 19 genes (EPSTI1, IFI44, IFI44L, IFIT1, IFIT2, IFIT3, MX1, OAS1, SAMD9L, PSMB9, STAT1, HERC5, EV12B, CD53, SELL, HLA-DQA1, PTPRC, B2M, and TAP2) with highest classification accuracy rate (95.7 %). Moreover, we validated our results by reproducing the same gene expression profile as a discriminatory test in the "test set," which included data from salivary gland samples of 15 patients with SS and 22 controls with 94.6 % accuracy. We propose that gene expression profile in the saliva or salivary glands could represent a promising simple and reproducible diagnostic biomarker for SS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25327574     DOI: 10.1007/s00296-014-3152-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  40 in total

1.  Frequency and predictive value of the clinical manifestations in Sjögren's syndrome.

Authors:  I Al-Hashimi; S Khuder; N Haghighat; M Zipp
Journal:  J Oral Pathol Med       Date:  2001-01       Impact factor: 4.253

Review 2.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 3.  Pathogenesis of Sjögren's syndrome.

Authors:  R I Fox; H I Kang
Journal:  Rheum Dis Clin North Am       Date:  1992-08       Impact factor: 2.670

4.  Chitinases in the salivary glands and circulation of patients with Sjögren's syndrome: macrophage harbingers of disease severity.

Authors:  Teresa Greenwell-Wild; Niki M Moutsopoulos; Maria Gliozzi; Efstathia Kapsogeorgou; Zoila Rangel; Peter J Munson; Haralampos M Moutsopoulos; Sharon M Wahl
Journal:  Arthritis Rheum       Date:  2011-10

5.  Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues.

Authors:  Xijin Ge; Shogo Yamamoto; Shuichi Tsutsumi; Yutaka Midorikawa; Sigeo Ihara; San Ming Wang; Hiroyuki Aburatani
Journal:  Genomics       Date:  2005-08       Impact factor: 5.736

6.  EVI2B, a gene lying in an intron of the neurofibromatosis type 1 (NF1) gene, is as the NF1 gene involved in differentiation of melanocytes and keratinocytes and is overexpressed in cells derived from NF1 neurofibromas.

Authors:  D Kaufmann; S Gruener; F Braun; M Stark; J Griesser; S Hoffmeyer; B Bartelt
Journal:  DNA Cell Biol       Date:  1999-05       Impact factor: 3.311

7.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.

Authors:  Emily C Baechler; Franak M Batliwalla; George Karypis; Patrick M Gaffney; Ward A Ortmann; Karl J Espe; Katherine B Shark; William J Grande; Karis M Hughes; Vivek Kapur; Peter K Gregersen; Timothy W Behrens
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

8.  Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome.

Authors:  Jacques-Eric Gottenberg; Nicolas Cagnard; Carlo Lucchesi; Franck Letourneur; Sylvie Mistou; Thierry Lazure; Sebastien Jacques; Nathalie Ba; Marc Ittah; Christine Lepajolec; Marc Labetoulle; Marc Ardizzone; Jean Sibilia; Catherine Fournier; Gilles Chiocchia; Xavier Mariette
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

9.  Gene interaction at HLA-DQ enhances autoantibody production in primary Sjögren's syndrome.

Authors:  J B Harley; M Reichlin; F C Arnett; E L Alexander; W B Bias; T T Provost
Journal:  Science       Date:  1986-05-30       Impact factor: 47.728

Review 10.  The role of type 1 interferon in systemic sclerosis.

Authors:  Minghua Wu; Shervin Assassi
Journal:  Front Immunol       Date:  2013-09-06       Impact factor: 7.561

View more
  14 in total

Review 1.  Primary Sjögren's syndrome: clinical phenotypes, outcome and the development of biomarkers.

Authors:  Andreas V Goules; Athanasios G Tzioufas
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

2.  Autoimmune manifestations in aged mice arise from early-life immune dysregulation.

Authors:  Tamer I Mahmoud; Jingya Wang; Jodi L Karnell; Qiming Wang; Shu Wang; Brian Naiman; Phillip Gross; Philip Z Brohawn; Chris Morehouse; Jordan Aoyama; Clive Wasserfall; Laura Carter; Mark A Atkinson; David V Serreze; Helen Braley-Mullen; Tomas Mustelin; Roland Kolbeck; Ronald Herbst; Rachel Ettinger
Journal:  Sci Transl Med       Date:  2016-10-19       Impact factor: 17.956

3.  High salivary soluble L-selectin and interleukin-7 levels in Asian Indian patients with primary Sjögren's syndrome.

Authors:  Jayakanthan Kabeerdoss; Pulukool Sandhya; Santosh Kumar Mandal; Mahasampath Gowri; Debashish Danda
Journal:  Clin Rheumatol       Date:  2016-09-12       Impact factor: 2.980

Review 4.  Saliva in the diagnosis of diseases.

Authors:  Chen-Zi Zhang; Xing-Qun Cheng; Ji-Yao Li; Ping Zhang; Ping Yi; Xin Xu; Xue-Dong Zhou
Journal:  Int J Oral Sci       Date:  2016-09-29       Impact factor: 6.344

5.  Hepatic expression profiles in retroviral infection: relevance to drug hypersensitivity risk.

Authors:  Yat Yee Wong; Brian Johnson; Thomas C Friedrich; Lauren A Trepanier
Journal:  Pharmacol Res Perspect       Date:  2017-04-26

6.  Elevated CCL19/CCR7 Expression During the Disease Process of Primary Sjögren's Syndrome.

Authors:  Zhenwei Liu; Fengxia Li; Axiao Pan; Huangqi Xue; Shan Jiang; Chengwei Zhu; Mengmeng Jin; Jinxia Fang; Xiaochun Zhu; Matthew A Brown; Xiaobing Wang
Journal:  Front Immunol       Date:  2019-04-24       Impact factor: 7.561

7.  Differential long non-coding RNA expression profile and function analysis in primary Sjogren's syndrome.

Authors:  Xiaochan Chen; Qi Cheng; Yan Du; Lei Liu; Huaxiang Wu
Journal:  BMC Immunol       Date:  2021-07-20       Impact factor: 3.615

Review 8.  Oral Health: The Need for Both Conventional Microbial and Molecular Characterization.

Authors:  Elisheva Friedman; Negin Alizadeh; Zvi Loewy
Journal:  High Throughput       Date:  2017-08-01

9.  Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma.

Authors:  Hongzhe Li; Xinjing Wang; Yuan Fang; Zhen Huo; Xiongxiong Lu; Xi Zhan; Xiaxin Deng; Chenghong Peng; Baiyong Shen
Journal:  Oncotarget       Date:  2017-03-31

10.  Type I Interferon Signaling Is Required for Dacryoadenitis in the Nonobese Diabetic Mouse Model of Sjögren Syndrome.

Authors:  Yury Chaly; Jennifer Y Barr; David A Sullivan; Helen E Thomas; Thomas C Brodnicki; Scott M Lieberman
Journal:  Int J Mol Sci       Date:  2018-10-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.